GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (STU:MAH0) » Definitions » Equity-to-Asset

Mereo BioPharma Group (STU:MAH0) Equity-to-Asset : 0.82 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Mereo BioPharma Group Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Mereo BioPharma Group's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €65.36 Mil. Mereo BioPharma Group's Total Assets for the quarter that ended in Sep. 2024 was €79.96 Mil.

The historical rank and industry rank for Mereo BioPharma Group's Equity-to-Asset or its related term are showing as below:

STU:MAH0' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.24   Med: 0.68   Max: 0.91
Current: 0.82

During the past 9 years, the highest Equity to Asset Ratio of Mereo BioPharma Group was 0.91. The lowest was -0.24. And the median was 0.68.

STU:MAH0's Equity-to-Asset is ranked better than
69.58% of 1512 companies
in the Biotechnology industry
Industry Median: 0.67 vs STU:MAH0: 0.82

Mereo BioPharma Group Equity-to-Asset Historical Data

The historical data trend for Mereo BioPharma Group's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Equity-to-Asset Chart

Mereo BioPharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.47 -0.24 0.70 0.66 0.76

Mereo BioPharma Group Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.76 0.77 0.82 0.82

Competitive Comparison of Mereo BioPharma Group's Equity-to-Asset

For the Biotechnology subindustry, Mereo BioPharma Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mereo BioPharma Group's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's Equity-to-Asset falls into.



Mereo BioPharma Group Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Mereo BioPharma Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=46.342/60.98
=0.76

Mereo BioPharma Group's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=65.355/79.96
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mereo BioPharma Group  (STU:MAH0) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Mereo BioPharma Group Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group Business Description

Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group Headlines

No Headlines